Vipivotide tetraxetan (PSMA-617) is primarily used in targeted radionuclide therapy for prostate cancer. It binds specifically to prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. Once bound, it delivers a radioactive isotope, such as lutetium-177, directly to the cancer cells, minimizing damage to surrounding healthy tissues. This makes it an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited therapeutic alternatives. Its precision in targeting cancer cells helps improve outcomes and reduce side effects compared to traditional therapies.